IN2014DN03213A - - Google Patents

Info

Publication number
IN2014DN03213A
IN2014DN03213A IN3213DEN2014A IN2014DN03213A IN 2014DN03213 A IN2014DN03213 A IN 2014DN03213A IN 3213DEN2014 A IN3213DEN2014 A IN 3213DEN2014A IN 2014DN03213 A IN2014DN03213 A IN 2014DN03213A
Authority
IN
India
Prior art keywords
prophylaxis
peptides
proteins
diseases
processes
Prior art date
Application number
Other languages
English (en)
Inventor
Ingo Flamme
Johannes Köbberling
Hans Georg Lerchen
Nils Griebenow
Loop Rudolf Schohe
Sven Wittrock
Ursula Krenz
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of IN2014DN03213A publication Critical patent/IN2014DN03213A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/05Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C5/00Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
    • C07C5/02Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by hydrogenation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN3213DEN2014 2011-11-03 2012-10-29 IN2014DN03213A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11187737 2011-11-03
PCT/EP2012/071373 WO2013064455A1 (en) 2011-11-03 2012-10-29 Tyrosine based linkers for the releasable connection of peptides

Publications (1)

Publication Number Publication Date
IN2014DN03213A true IN2014DN03213A (de) 2015-05-22

Family

ID=47088883

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3213DEN2014 IN2014DN03213A (de) 2011-11-03 2012-10-29

Country Status (16)

Country Link
US (1) US9315543B2 (de)
EP (1) EP2773375B1 (de)
JP (1) JP6051223B2 (de)
KR (1) KR20150000464A (de)
CN (1) CN104144705B (de)
AU (1) AU2012331279A1 (de)
BR (1) BR112014010806A2 (de)
CA (1) CA2854095C (de)
EA (1) EA026184B1 (de)
ES (1) ES2624626T3 (de)
HK (1) HK1198926A1 (de)
IL (1) IL232152A0 (de)
IN (1) IN2014DN03213A (de)
MX (1) MX2014004953A (de)
WO (1) WO2013064455A1 (de)
ZA (1) ZA201402939B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190001B1 (ar) * 2011-11-03 2022-03-14 Bayer Pharma AG عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه
AU2015323769A1 (en) 2014-09-26 2017-04-13 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
US11207991B2 (en) * 2016-12-15 2021-12-28 Ford Global Technologies, Llc Vehicle charging system for DC fast charging electrified vehicles
AU2018302022A1 (en) 2017-07-17 2020-02-27 Macregen, Inc. Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
CN110591077B (zh) * 2019-10-17 2022-01-07 江南大学 一种酶催化制备酪氨酸寡肽和接枝单甲氧基聚乙二醇的方法
MX2022012332A (es) * 2020-04-03 2022-10-27 Bayer Ag Formulaciones farmaceuticas liquidas de profarmacos a base de polietilenglicol de adrenomedulina y su uso.
CN112457218B (zh) * 2020-11-05 2022-08-09 宁夏医科大学 2,4-二氨基丁酸衍生物的合成方法
IL310248A (en) 2021-08-20 2024-03-01 Bayer Ag A process for the preparation of polyethylene glycol-modified adrenomedullin, its intermediates and their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP1243276A1 (de) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Langgestreckte und mehrfachige Abstandhaltern enthaltende aktivierbare Prodroge
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
EP2087910B1 (de) 2004-03-23 2022-05-04 Ascendis Pharma GmbH Polymer-Prodrugs
JP2007531735A (ja) * 2004-04-01 2007-11-08 エラン ファーマシューティカルズ,インコーポレイテッド ステロイド節約剤および該節約剤を使用する方法
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2008075968A1 (en) * 2006-12-20 2008-06-26 Ge Healthcare As Contrast agents
CN101641119A (zh) * 2006-12-20 2010-02-03 通用电气医疗集团股份有限公司 造影剂
WO2009092073A2 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects
ES2833035T3 (es) * 2009-07-31 2021-06-14 Ascendis Pharma As Hidrogeles biodegradables insolubles en agua a base de polietilenglicol
JOP20190001B1 (ar) * 2011-11-03 2022-03-14 Bayer Pharma AG عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه

Also Published As

Publication number Publication date
JP6051223B2 (ja) 2016-12-27
BR112014010806A2 (pt) 2017-05-02
CN104144705A (zh) 2014-11-12
EP2773375A1 (de) 2014-09-10
MX2014004953A (es) 2014-05-28
CA2854095C (en) 2021-03-30
EA026184B1 (ru) 2017-03-31
CA2854095A1 (en) 2013-05-10
IL232152A0 (en) 2014-05-28
EP2773375B1 (de) 2017-02-08
WO2013064455A1 (en) 2013-05-10
US9315543B2 (en) 2016-04-19
KR20150000464A (ko) 2015-01-02
EA201490901A1 (ru) 2014-10-30
US20150051160A1 (en) 2015-02-19
JP2014533244A (ja) 2014-12-11
HK1198926A1 (en) 2015-06-19
ES2624626T3 (es) 2017-07-17
ZA201402939B (en) 2015-11-25
CN104144705B (zh) 2017-03-01
AU2012331279A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
IN2014DN03213A (de)
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX2013013913A (es) Polipeptidos.
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
WO2013084000A3 (en) Exosomes for delivery of biotherapeutics
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
TN2012000414A1 (en) Forms of rifaximin and uses thereof
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
UA111098C2 (uk) Проліки адреномедуліну на основі поліетиленгліколю і їх застосування
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
EA201391440A1 (ru) Производные пиразолопиримидина
PH12014501200A1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
UA114298C2 (uk) Пептид торк та вакцина, що його містить
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
MX2016005976A (es) Formulaciones de tripeptido liofilizado estables en almacenamiento.
WO2014039074A3 (en) Therapeutic compositions and related methods
GB201118201D0 (en) Novel peptides
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.